» Articles » PMID: 29983043

Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2018 Jul 10
PMID 29983043
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibitors of the human enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH1) can control endogenous nitric oxide production. A time-dependent covalent inactivator of DDAH1, N-(1-imino-2-chloroethyl)-l-ornithine ( K = 1.3 μM, k = 0.34 min), was conceptually dissected into two fragments and each characterized separately: l-norvaline ( K = 470 μM) and 2-chloroacetamidine ( K = 310 μM, k = 4.0 min). This analysis suggested that the two fragments were not linked in a manner that allows either to reach full affinity or reactivity, prompting the synthesis and characterization of three analogues: two that mimic the dimethylation status of the substrate, N-(1-imino-2-chloroisopropyl)-l-ornithine ( k /K = 208 M s) and N-(1-imino-2-chlorisopropyl)-l-lysine ( k /K = 440 M s), and one that lengthens the linker beyond that found in the substrate, N-(1-imino-2-chloroethyl)-l-lysine (Cl-NIL, K = 0.19 μM, k = 0.22 min). Cl-NIL is one of the most potent inhibitors reported for DDAH1, inactivates with a second order rate constant (1.9 × 10 M s) larger than the catalytic efficiency of DDAH1 for its endogenous substrate (1.6 × 10 M s), and has a partition ratio of 1 with a >100 000-fold selectivity for DDAH1 over arginase. An activity-based protein-profiling probe is used to show inhibition of DDAH1 within cultured HEK293T cells (IC = 10 μM) with cytotoxicity appearing only at higher concentrations (ED = 118 μM). A 1.91 Å resolution X-ray crystal structure reveals specific interactions made with DDAH1 upon covalent inactivation by Cl-NIL. Dissecting a covalent inactivator and analysis of its constituent fragments proved useful for the design and optimization of this potent and effective DDAH1 inhibitor.

Citing Articles

A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase.

Ragavan V, Nair P, Jarzebska N, Angom R, Ruta L, Bianconi E Nat Commun. 2023; 14(1):3392.

PMID: 37296100 PMC: 10256801. DOI: 10.1038/s41467-023-38467-9.

References
1.
Cardounel A, Cui H, Samouilov A, Johnson W, Kearns P, Tsai A . Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2006; 282(2):879-87. DOI: 10.1074/jbc.M603606200. View

2.
Wang Y, Hu S, Fast W . A click chemistry mediated in vivo activity probe for dimethylarginine dimethylaminohydrolase. J Am Chem Soc. 2009; 131(42):15096-7. PMC: 2782550. DOI: 10.1021/ja906432e. View

3.
Tuley A, Fast W . The Taxonomy of Covalent Inhibitors. Biochemistry. 2018; 57(24):3326-3337. PMC: 6016374. DOI: 10.1021/acs.biochem.8b00315. View

4.
Brunger A . Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Crystallogr D Biol Crystallogr. 1993; 49(Pt 1):24-36. DOI: 10.1107/S0907444992007352. View

5.
Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View